Search results
Results from the WOW.Com Content Network
The Quality of drugs and Active Pharmaceutical Ingredients (API) made by Chinese pharmaceutical companies is often poor. In the past three years 2015–2017, there were 35 FDA warning letters to Chinese pharmaceutical companies citing serious Data Integrity issues, including data deletion or manipulation or fabrication of test results, see "An Analysis of 2017 FDA Warning Letters on Data ...
The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical. Its H shares were listed on the Hong Kong Stock Exchange in 2009, [2] with its IPO price of HK$16 per share.
China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise.The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine [] (SEHK: 570, mostly via ...
According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the ...
Code Short-name Full name Listing date Issued capital Negotiable capital Industry Http English Chinese 000100: TCL: TCL集团: TCL Corporation: 30.01.2004: 13,549,648,507
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (trade name: Fosun Pharma) is a Chinese pharmaceutical company.It is mostly owned by Fosun International. [2]As of 2018, the A shares of the company is a constituent of SSE 180 Index as well as its sub-index SSE MidCap Index. [3]
Sino Biopharmaceutical Limited (SEHK: 1177|Hang Seng Index component) (simplified Chinese: 中国生物制药有限公司; traditional Chinese: 中國生物製藥有限公司), shortly Sino Biopharm, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent ...
Shanghai Pharma is the largest pharmaceutical and the first A+H listed company in China to be dual-listed by Shanghai and Hong Kong Stock Exchanges. [2] [3] As of year 2020, the company made its presence to the Global Fortune 500 list with the ranking of 473, overall and 124 among 21 other Chinese companies on the list. [2] [4]